Dr. Ozkaynak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
19 Bradhurst Ave
Ste. 1400
Hawthorne, NY 10532Phone+1 914-493-7997Fax+1 914-594-4022
Education & Training
- Children's Hospital Los AngelesResidency, Pediatrics, 1989 - 1991
- Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 1986 - 1989
- Hacettepe University FOMClass of 1978
Certifications & Licensure
- CA State Medical License 1990 - Present
- NY State Medical License 1994 - 2026
- CT State Medical License 1997 - 2025
- ME State Medical License Active through 2006
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2010-2014
- Westchester Magazine: Top Doctors Castle Connolly, 2011
Clinical Trials
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
- Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Start of enrollment: 2004 Mar 15
- Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsEfficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803andin NB xenografts.Yaya Chu, Gaurav Nayyar, Meijuan Tian, Dean A Lee, Mehmet F Ozkaynak
Molecular Therapy. Oncology. 2024-06-20 - 13 citationsOutcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B London
Journal of Clinical Oncology. 2022-12-10 - 98 citationsLong-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Arlene Naranjo, Mitchell B. Diccianni
Clinical Cancer Research. 2021-04-15
Journal Articles
- The Safety and Efficacy of Clofarabine in Combination with High-Dose Cytarabine and Total Body Irradiation Myeloablative Conditioning and Allogeneic Stem Cell Transpla...Stacey Zahler, Mitchell S Cairo, Jennifer Krajewski, M Fevzi Ozkaynak, Alexandra C Cheerva, Theodore B Moore, Alfred P Gillio, Mark C Walters, Nature
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: